Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis

Overview of attention for article published in BMC Neurology, December 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

blogs: 1 blog
policy: 1 policy source

facebook: 1 Facebook page

Citations

dimensions_citation: 39 Dimensions

Readers on

mendeley: 72 Mendeley

Summary Blogs Policy documents Facebook Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Peginterferon beta-1a

Cited by Canadian Agency for Drugs and Technologies in Health on 07 Sep 2018

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.